Microbix Biosystems (TSE:MBX) Director Martin Marino Buys 52,500 Shares

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino purchased 52,500 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was acquired at an average price of C$0.24 per share, for a total transaction of C$12,600.00. Following the completion of the purchase, the director owned 1,744,167 shares of the company’s stock, valued at approximately C$418,600.08. This represents a 3.10% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Monday, December 22nd, Martin Marino acquired 100,000 shares of Microbix Biosystems stock. The stock was acquired at an average price of C$0.23 per share, with a total value of C$23,000.00.

Microbix Biosystems Price Performance

Microbix Biosystems stock opened at C$0.22 on Friday. The company has a market cap of C$30.54 million, a P/E ratio of -13.75 and a beta of 0.03. Microbix Biosystems Inc. has a one year low of C$0.21 and a one year high of C$0.55. The business has a fifty day moving average of C$0.24 and a two-hundred day moving average of C$0.25. The company has a debt-to-equity ratio of 22.61, a quick ratio of 5.57 and a current ratio of 7.15.

Microbix Biosystems (TSE:MBX) last posted its quarterly earnings results on Thursday, December 18th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$3.74 million for the quarter. Microbix Biosystems had a return on equity of 12.65% and a net margin of 13.86%. As a group, analysts predict that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.